Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors

Podobne zapisy

• SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
  od: El Mouhayyar, Christopher, i wsp.
  Wydane: (2020)
• The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
  od: Schernthaner, Guntram, i wsp.
  Wydane: (2014)
• SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
  od: Aryan Gajjar, i wsp.
  Wydane: (2025-08-01)
• COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR
  od: DeFronzo, Ralph A.
  Wydane: (2017)
• The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
  od: de Wit, Helena M., i wsp.
  Wydane: (2016)